The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The closing price of Dexcom Inc (NASDAQ: DXCM) was $128.14 for the day, up 0.57% from the previous closing price of $127.42. In other words, the price has increased by $0.57 from its previous closing price. On the day, 1.46 million shares were traded. DXCM stock price reached its highest trading level at $130.48 during the session, while it also had its lowest trading level at $127.62.
Ratios:
Our analysis of DXCM’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 17.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 87.33. For the most recent quarter (mrq), Quick Ratio is recorded 2.53 and its Current Ratio is at 2.90. In the meantime, Its Debt-to-Equity ratio is 1.15 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, RBC Capital Mkts on March 12, 2024, initiated with a Outperform rating and assigned the stock a target price of $165.
Raymond James Upgraded its Outperform to Strong Buy on April 17, 2023, whereas the target price for the stock was revised from $127 to $138.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 30 ’24 when Brown Michael Jon sold 629 shares for $126.25 per share. The transaction valued at 79,411 led to the insider holds 68,212 shares of the business.
Dolan Matthew Vincent sold 1,990 shares of DXCM for $274,242 on Apr 15 ’24. The EVP Strategy and Corporate Dev now owns 42,377 shares after completing the transaction at $137.81 per share. On Apr 08 ’24, another insider, SAYER KEVIN R, who serves as the President CEO and Chairman of the company, sold 49,633 shares for $138.30 each. As a result, the insider received 6,864,136 and left with 283,893 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DXCM now has a Market Capitalization of 50959228928 and an Enterprise Value of 50652307456. As of this moment, Dexcom’s Price-to-Earnings (P/E) ratio for their current fiscal year is 82.72, and their Forward P/E ratio for the next fiscal year is 56.84. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.30. For the stock, the TTM Price-to-Sale (P/S) ratio is 13.40 while its Price-to-Book (P/B) ratio in mrq is 22.59. Its current Enterprise Value per Revenue stands at 13.323 whereas that against EBITDA is 59.696.
Stock Price History:
Over the past 52 weeks, DXCM has reached a high of $142.00, while it has fallen to a 52-week low of $74.75. The 50-Day Moving Average of the stock is -3.25%, while the 200-Day Moving Average is calculated to be 11.57%.
Shares Statistics:
DXCM traded an average of 3.14M shares per day over the past three months and 3130430 shares per day over the past ten days. A total of 397.68M shares are outstanding, with a floating share count of 391.29M. Insiders hold about 1.61% of the company’s shares, while institutions hold 95.82% stake in the company. Shares short for DXCM as of 1713139200 were 11771906 with a Short Ratio of 3.75, compared to 1710460800 on 15866558. Therefore, it implies a Short% of Shares Outstanding of 11771906 and a Short% of Float of 3.36.
